Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 10
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Smiraldo, Phillip G. Tang, Jun Shay, Jerry W. and Wright, Woodring E. 2012. Telomerases.

    Lin, Po-Cheng Lin, Shinn-Zong Chen, Yi-Lin Chang, Jeng-Shou Ho, Li-Ing Liu, Po-Yen Chang, Li-Fu Harn, Yeu-Chern Chen, Shee-Ping Sun, Li-Yi Huang, Pi-Chun Chein, Jung-Ting Tsai, Chang-Hai Chou, Chii-Wen Harn, Horng-Jyh and Chiou, Tzyy-Wen 2011. Butylidenephthalide Suppresses Human Telomerase Reverse Transcriptase (TERT) in Human Glioblastomas. Annals of Surgical Oncology, Vol. 18, Issue. 12, p. 3514.

    Kryukov, Fedor Očadlíková, Darina Kovářová, Lucie Burešová, Ivana Hájek, Roman and Michálek, Jaroslav 2009. In vitroactivation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells. Journal of Immunotoxicology, Vol. 6, Issue. 4, p. 243.

    Shervington, Amal Patel, Rahima Lu, Chen Cruickshanks, Nichola Lea, Robert Roberts, Gareth Dawson, Tim and Shervington, Leroy 2007. Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Research, Vol. 1134, p. 45.

    Brümmendorf, Tim H. 2005. Telomerase Activity – a Prognostic Factor in Colorectal Cancer?. Oncology Research and Treatment, Vol. 28, Issue. 11, p. 550.

    Ghosh, Utpal and Bhattacharyya, Nitai P. 2005. Benzamide and 4-amino 1,8 naphthalimide treatment inhibit telomerase activity by down-regulating the expression of telomerase associated protein and inhibiting the poly(ADP-ribosyl)ation of telomerase reverse transcriptase in cultured cells. FEBS Journal, Vol. 272, Issue. 16, p. 4237.

    Keith, W Nicol Bilsland, Alan Hardie, Maryon and Evans, TR Jeffry 2004. Drug Insight: cancer cell immortality—telomerase as a target for novel cancer gene therapies. Nature Clinical Practice Oncology, Vol. 1, Issue. 2, p. 88.

    Álvarez-Núñez, Francisco Mora, Josefina Matías-Guiu, Xavier and de Leiva Hidalgo, A. 2003. Carcinoma tiroideo del epitelio folicular: marcadores tumorales y oncogenes. Medicina Clínica, Vol. 121, Issue. 7, p. 264.

    Chen, Zhi and Corey, David R. 2003.

    Saretzki, Gabriele 2003. Telomerase inhibition as cancer therapy. Cancer Letters, Vol. 194, Issue. 2, p. 209.


Telomerase-directed molecular therapeutics

  • W. Nicol Keith (a1), Alan Bilsland (a1), T.R. Jeffry Evans (a1) and Rosalind M. Glasspool (a1)
  • DOI:
  • Published online: 01 April 2002

The management of malignant disease remains one of the most challenging areas of modern medicine. The lifetime risk of developing cancer in the western world is estimated to be as high as 1 in 3. Traditionally, surgery, chemotherapy and radiotherapy have been the primary choice of treatment for patients with malignant tumours. Despite advances in the use and development of conventional cytotoxic agents, the cure rate remains disappointing in most patients with advanced disease of the common solid tumours. Consequently, the development of novel anti-cancer therapies is a high priority in cancer medicine. In recent years, a new generation of cancer therapies has emerged, based on a growing understanding of the molecular events that contribute to malignant transformation. A major difference between normal and cancer cells is the ability of cancer cells to multiply in an unrestricted and ungoverned fashion. In this context, there is considerable interest in elucidating the mechanisms that allow this unrestricted proliferation and that ultimately result in immortal cancer cells. It is now clear that the enzyme telomerase confers immortality on cells in most types of cancer. With the cancer cell reliant on telomerase for its survival, telomerase represents an extremely attractive mechanism-based target for the development of new cancer therapeutics.

Corresponding author
Cancer Research UK Department of Medical Oncology, University of Glasgow, Cancer Research UK Beatson Laboratories, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, UK. Tel: +44 141 330 4811; Fax: +44 141 330 4127; E-mail:
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *